Trump Administration Executive Order on Gender: Ongoing Impact
- This text details concerning changes at the CDC that appear to be driven by a new focus on "gender ideology" and a rigid definition of biological sex, and...
- * The department of Health and Human Services (HHS) issued guidance limiting the definition of sex to biological characteristics, impacting federal agencies.
- * The CDC updated its "about" page to prioritize recognizing sex as "unchangeable" and based on "objective biology." * This prioritizes a specific viewpoint on gender and...
Summary of CDC Actions and Potential Impacts on LGBTQ+ Health
This text details concerning changes at the CDC that appear to be driven by a new focus on “gender ideology” and a rigid definition of biological sex, and outlines the potential negative consequences for LGBTQ+ public health. Here’s a breakdown of the key points:
1. Policy Shifts & Limiting Understanding:
* The department of Health and Human Services (HHS) issued guidance limiting the definition of sex to biological characteristics, impacting federal agencies.
* This shift is seen as limiting understanding of LGBTQ+ experiences and hindering the advancement of effective, responsive policies.
2. CDC “About” page & Agency Priorities:
* The CDC updated its “about” page to prioritize recognizing sex as “unchangeable” and based on “objective biology.”
* This prioritizes a specific viewpoint on gender and sex, potentially impacting public health messaging and services.
* This shift is especially concerning given the elevated health risks faced by the LGBTQ+ community, including higher rates of HIV.
* It could erode trust in the CDC, which is crucial for effective public health responses (like the mpox outbreak).
* Funding opportunities aligned with this new priority could jeopardize grants for organizations serving gender-diverse communities.
3. Omission of Transgender People in Clinical Guidelines:
* recent CDC clinical guidelines are omitting mention of transgender people.
* Specifically, guidelines for the new HIV prevention drug, lenacapavir (PrEP), do not mention transgender or non-binary individuals, despite their inclusion in the clinical trials that proved the drug’s effectiveness.
* The PURPOSE 2 trial specifically included and demonstrated the drug’s efficacy in transgender men and women, and non-binary people (96%-100% effective).
* The FDA drug label confirms no significant differences in drug effectiveness based on gender identity.
* This is a departure from the CDC’s 2021 PrEP guidelines, which did include a section on PrEP for transgender people, and from the WHO’s approach to the drug.
Overall Impact:
The author argues these changes represent a departure from established public health principles – specifically, tailoring approaches to communities with high unmet needs and acknowledging their existence in a culturally competent way. The omission of LGBTQ+ individuals from guidelines and messaging could lead to:
* Gaps in knowledge about LGBTQ+ health needs.
* Difficulty monitoring and responding to health disparities.
* Reduced trust in the CDC.
* Limited access to vital services.
In essence, the text paints a picture of the CDC potentially moving away from inclusive, evidence-based public health practices towards a more restrictive and potentially harmful approach regarding LGBTQ+ health.